Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
about
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaStructural reengineering of imatinib to decrease cardiac risk in cancer therapyEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaRole for the Unfolded Protein Response in Heart Disease and Cardiac ArrhythmiasGetting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyPharmacology and rationale for imatinib in the treatment of sclerodermaCardiac effects of anticancer therapy in the elderlyOverview and management of cardiac adverse events associated with tyrosine kinase inhibitorsTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment courseUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsCardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitorOverexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibitionMitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.Principal component analysis-based unsupervised feature extraction applied to in silico drug discovery for posttraumatic stress disorder-mediated heart diseaseTranscriptional profiling of the dose response: a more powerful approach for characterizing drug activitiesAbl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survivalGSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in miceImatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategyTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Adaptability in protein structures: structural dynamics and implications in ligand design.Intersection of cardiology and oncology clinical practices.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunctionActivity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.A cell-based biosensor for real-time detection of cardiotoxicity using lensfree imaging.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
P2860
Q21142738-1247D400-965A-4FAD-9E3F-21C299808DF5Q24605527-31E5B063-A303-43BA-914B-1AEFDF80B1EBQ24685557-24FB745D-79F0-4CA3-9E4C-75228847313EQ26749324-0D8160A0-8663-4AC6-9EDF-0FAA9993D555Q26771256-C4964972-A5D0-4372-B0FA-09978A72767EQ26797138-81B1F5A7-E0BB-410F-94E3-03D31D01BE04Q26825153-F514DF22-FFC5-4E03-BD16-63C1528E5A1DQ26863244-BDA97075-564A-4508-B21A-99B78F46639CQ26865766-4FA35054-D434-4FDD-91F5-2AD2441B5F20Q27013665-38F00BED-8CF5-48A7-9282-576AFCB97A83Q27023074-F652487F-F47A-49CF-AD93-9F0337C0E662Q27027354-D48C3E71-0DF0-4871-BD5A-92689A4005CAQ28087776-769CE45B-644D-4045-81E3-DB8F7A0A4F34Q28276103-00EFF9E5-D474-4968-BF6C-7259370AC8E3Q28281770-986A4694-B09E-4FD4-AA05-EFFC6767B1A3Q28296128-37E5ABAD-E0C9-43E8-9202-F62583C62304Q28395122-ADA5732F-417B-43CB-BD7C-B26CAE07298FQ28476104-5F1D7877-6751-437D-9764-9576D15D567DQ28586705-446DCA95-DB39-4714-90F3-A37119EBCFA8Q28590516-6C2B59F9-F1AF-4A07-9F42-E9041771BFE2Q30008882-EE34FBB6-327E-42FE-A634-1CEB7FDFDF90Q30242015-4D384F9B-78D9-41E4-8310-01F8CEEA18DCQ30357974-81A08771-E570-4918-887D-623A25065A7BQ30428702-6A81CD5D-7F53-4EC6-BE4D-9806A252E0CAQ30446453-4B9CC239-96AA-4A8C-B6CD-20C09C32A1D1Q30485073-35A1EC8B-0601-48E1-8207-9E75898EBF8EQ30492863-5AE0393E-475D-4606-993F-29F451CC0320Q30538150-36B91666-0B7D-40E5-8720-816E861245A0Q30847302-4FB2E755-836A-42B2-9D01-97F054ED70ADQ30884142-7125BF74-BDEF-4422-B411-243E87476738Q31037843-2FB739B8-EA39-4FAF-A907-A1F84C3BFBC4Q33308713-AF6B34B0-4E60-4138-9E0D-18A69DEC60EAQ33383954-7262E9B6-8D91-4ED2-BC48-DB12DB9C6A62Q33392977-36B2ABB5-1629-4718-880E-B2654A0080B4Q33401360-E6DABA6C-E4E6-4BBA-96D0-EEEE8EDAC976Q33408049-B7A2BE4B-4DFA-4452-90FA-972ABBDD88E6Q33419794-A81B71DF-C6AC-4BCA-A341-54E52AC8B1CCQ33482818-565CDD60-0786-48D9-BBEC-6ABE7A4D9281Q33569566-18F5750A-E977-479B-8C16-69FB15FC3936Q33573760-607EF0EE-F848-4ECF-A468-B64113EFE631
P2860
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
@ast
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
@en
type
label
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
@ast
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
@en
prefLabel
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
@ast
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
@en
P2093
P356
P1433
P1476
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
@en
P2093
Anthony Rosenzweig
Brian Walters
Cara Beahm
Cezar Iliescu
Fred J Clubb
Jean-Bernard Durand
Joseph Alroy
Luanda Grazette
Richard A Van Etten
Richard Patten
P2888
P304
P356
10.1038/NM1446
P407
P50
P577
2006-07-23T00:00:00Z